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CONCISE COMMUNICATION 
Allopurinol mouthwashes in methotrexate-induced 
stomatitis 
Some preliminary studies have shown that allopuri- 
no1 mouthwashes are effective treatment for 5-fluorouracil 
(5-FU)-induced stomatitis (1,2). Since the systemic admin- 
istration of allopurinol does not improve the therapeutic 
ratio of 5-FU (3), a local action seems likely (2), possibly 
related to the anti-oxidant properties of this drug (43). If so, 
topical allopurinol could have a beneficial effect in stomatitis 
induced by antiproliferative agents other than 5-FU, includ- 
ing methotrexate (MTX). 
Oral ulcers are among the commonest side effects of 
MTX therapy in cancer patients and represent a frequent 
adverse experience in rheumatoid arthritis (RA) patients 
when treated with weekly low doses of the drug. Stomatitis, 
with or without oral ulcers, has been reported in 6 5 5 %  of 
MTX-treated RA patients (6-8). In some patients, oral 
soreness may become very troublesome, though it usually 
does not represent a primary reason for discontinuation of 
the drug (7). No specific treatment has been proposed so far. 
High-dose (45 mg/week) folinic acid supplementation might 
be effective, but it proved to worsen RA activity indexes in 
a prospective study (9). Low-dose folinic acid does not affect 
the efficacy of MTX (lo), but its beneficial effect is still 
controversial. Favorable results were obtained at our insti- 
tution in a placebo-controlled study of allopurinol mouth- 
washes for 5-FU-treated patients with colorectal cancer 
(1 1). We therefore decided to give allopurinol mouthwashes 
to our RA patients who had MTX-induced stomatitis. 
Allopurinol is generally well tolerated, with few 
significant adverse effects. However, a life-threatening tox- 
icity syndrome has been described after its use in patients 
with renal failure (12). Thus, only patients with normal 
serum creatinine levels and creatinine clearance values 
above 70 ml entered this study. All patients were fully 
informed about potential risks of allopurinol therapy, and the 
study design was approved by the Department of Internal 
Medicine and Therapeutics of the University of Pavia. 
We thus far have treated 6 patients with RA (accord- 
ing to the 1987 revised criteria of the American College of 
Rheumatology [ 131) and 1 with refractory dermatomyositis; 
their main clinical features are reported in Table 1. During 
MTX therapy (10-20 mg/week intramuscularly), all these 
patients had developed persistent stomatitis. Stomatitis was 
graded according to the Eastern Cooperative Oncology 
Group criteria (14): grade 0 = no stomatitis, grade 1 = 
soreness, grade 2 = ulcers present, but patient can eat, grade 
3 = ulcers present and patient cannot eat. The ulcers were 
painful and failed to respond to mouthwashes with topical 
anesthetics. 
The mouthwash suspension consisted of 5 mg/ml of 
allopurinol in water. It was prepared by dissolving 300 mg of 
allopurinol granular dispersion (Zyloric; Wellcome Italia, 
Pomezia, Italy) in 60 ml of water. The patients were in- 
structed to mix the suspension well before using and not to 
swallow the mouthwash. Each 60-ml suspension was suffi- 
cient for 2-4 mouthwashes. Allopurinol mouthwashes were 
repeated 2 4  times every day for 3 consecutive days every 
week, starting from the day of MTX administration. The 
suggested duration of each mouthwash was 1 minute. The 
regimen was continued indefinitely. 
A very good response was found after the first 2 
courses of treatment and was maintained in subsequent 
courses. Oral ulcers completely healed in all patients, and 
soreness disappeared in 6 of the 7 patients. One patient had 
a recurrence of grade 2 stomatitis after withdrawal and had a 
new, complete response after restarting mouthwashes. No 
local or systemic side effect related to allopurinol treatment 
was observed during a followup period of 4-8 months. Two 
patients had preexisting nausea, which was not affected by 
allopurinol treatment. No deterioration in clinical and labo- 
ratory indexes of RA was found during allopurinol treat- 
ment. 
The daily absorbed dose through oral mucosa is 
likely to be consistently lower than that reached when the 
Table 1. Characteristics of patients treated with allopurinol mouthwashes for methotrexate (MTX)- 
induced stomatitis* 
Allopurinol treatment 
ESR Stomatitis 
score MTX Duration of Prednisone (mmlhour) 
Duration of weekly MTX daily 
Patient/ disease dosage therapy dosage Week Week Week Week 
diagnosis Agelsex (years) (mg) (months) (mg) 0 18 0 18 
I/DM 59lM 2 20 3 37.5 63 15 2 0 
2lRA @IF 29 10 9 - 22 24 2 0 
3MA 71IM 17 10 14 2.5 23 18 1 0 
4lRA 69lF 24 IS 8 1.5 I8 67 2 0 
5IRA 51IF 8 15 45 7.5 85 81 1 0 
6IRA 13lF 14 10 1 1  5 33 37 1 1 
IIRA 66lF 5 10 2 5 64 40 2 0 
* ESR = erythrocyte sedimentation rate (Westergren); DM = dermatomyositis; RA = rheumatoid 
arthritis. 
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same amount of allopurinol is ingested. However, since 
definite data on this topic are not available, allopurinol 
mouthwashes should be avoided in patients with reduced 
creatinine clearance (12). 
In conclusion, our pilot study suggests that allopuri- 
no1 mouthwashes may be effective in reducing oral discom- 
fort in MTY-treated RA patients. It is well tolerated and 
does not affect the underlying disease. Further controlled 
studies will be necessary to establish the clinical efficacy and 
safety of this regimen. 
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